A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.
Launched by HOFFMANN-LA ROCHE · Mar 16, 2010
Trial Information
Current as of May 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients, \>/=18 years of age
- • chronic hepatitis D
- • positive for HBsAg \>/=6 months, for anti-HDV \>/=3 months and for HDV-RNA at screening
- • negative pregnancy test; fertile males and women of childbearing age should use two reliable forms of contraception throughout study
- Exclusion Criteria:
- • antiviral therapy for chronic hepatitis D within the previous 6 months
- • previous therapy with pegylated interferon alfa
- • treatment with conventional interferon alfa for \>12 months
- • hepatitis A or C, or HIV infection
- • decompensated liver disease (Childs B-C)
- • history or evidence of medical condition associated with chronic liver disease
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, , Turkey
Bursa, , Turkey
Diyarbakir, , Turkey
Istanbul, , Turkey
Izmir, , Turkey
Izmir, , Turkey
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials